ClinicalTrials.gg
RecruitingNCT07333066REINFORCEUpdated Jun 17, 2026

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

A Phase 3 interventional study of Apalutamide (Erleada™) 60 mg or 240 mg tablets and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer, sponsored by Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD. Recruiting at 56 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Planned enrollment
22nd of 185
320 · median 39
Started
2026
with 6 others
Phase 3
30 of 193
5 open now
Primary completion
2030-03
later than 19 of 23 live
Registered
189th of 193
by date

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 22nd largest by planned enrollment of the 185 interventional ones that give a count, is one of 7 that started in 2026, is one of 30 in phase 3, reaches primary completion later than 19 of the 23 other live ones, and was the 189th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide and ADT, assessed by event-free survival, in patients with mHSPC who do not achieve deep PSA response (≤0,2 ng/ml or PSA90 response in combination with a PSA ≤ 4 ng/ml) after initial treatment with apalutamide and ADT. A non-deep PSA response is defined as PSA > 0.2 ng/ml in combination with a PSA response \< 90%, or a PSA response ≥90% in combination with a PSA > 4 ng/ml.

Read the detailed description

Approximately 320 patients will be randomized in a 1:1 ratio to the treatments as specified below:

  • Arm A (experimental arm): docetaxel (75 mg/m2 every three weeks), for 6 planned cycles, plus apalutamide and ADT (240 mg, oral single daily dose).
  • Arm B (control arm): continuation of SOC treatment with apalutamide and ADT (240 mg, oral single daily dose).

Randomization will be stratified by 3 factors:

  • Metastasis timing (synchronous vs metachronous)
  • Visceral metastasis at diagnosis (yes vs no)
  • PSA at study inclusion (≤ 4 ng/ml vs >4 ng/ml) An IDMC will be established for regular safety monitoring, for the pre-planned interim analysis and the PK sub-study when available. The composition, role, responsibilities and procedures of the IDMC will be detailed in the IDMC Charter.
03

Conditions studied

  • Metastatic Hormone-sensitive Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Apalutamide
  • Hormone-sensitive prostate cancer
  • Deep PSA response
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written . Each patient must sign an informed consent form (ICF) indicating that he understands the purpose of and procedures, required for the study, and is willing to participate in the study.
  2. Patient must be a man ≥18 years of age.
  3. or cytologically confirmed adenocarcinoma of prostate.
  4. hormone-sensitive prostate cancer.
  5. PSA >5 ng/ml at diagnosis of metastatic disease.
  6. Patients eligible to continue treatment with apalutamide and ADT and without to receive docetaxel.
  7. Patients with at least 24 weeks and no more than 30 weeks of apalutamide.
  8. Patients with a maximum of 12 weeks ADT before apalutamide initiation.
  9. Lack of achievement of deep PSA response after 24 weeks and no more than 30 weeks of apalutamide. Deep PSA response is defined as PSA ≤ 0.2 ng/ml or PSA response ≥ 90% in combination with a PSA ≤4 ng/ml. Therefore, a non-deep PSA response is defined as PSA > 0.2 ng/ml in combination with a PSA response \< 90%, or a PSA response ≥90% in combination with a PSA > 4 ng/ml.
  10. Patients who have not progressed to apalutamide.
  11. Patients that are tolerating adequately apalutamide 240 mg daily and with no toxicity higher than G1 at inclusion.
  12. Be able to swallow whole apalutamide film-coated tablets.
  13. (ECOG) performance status ≤ 1.
  14. Clinical laboratory values at screening:

    1. ≥10.0 g/dL,
    2. ≥1.5 × 10*9/L,
    3. count ≥100 × 109/L, The patient must not have received any growth factor within 4 weeks or a blood transfusion within 7 days of the hematology laboratory sample obtained at screening
    4. serum and/or aspartate transaminase ≤1.5 × the (ULN),
    5. total ≤ ULN,
    6. creatinine ≤2.0 × ULN
  15. Sexually active men must agree to use an external condom as an effective barrier method and refrain from sperm donation, and their female partners of must practice a highly effective method of during and for 3 months after treatment with apalutamide and for 6 months after treatment with docetaxel.

Exclusion criteria

Exclusion Criteria:

  1. Presence of neuroendocrine histology.
  2. Apalutamide treatment started more than 30 weeks before inclusion.
  3. Progression disease by any means, including radiographic, clinical or serological at inclusion.
  4. Patient who achieves deep PSA response on apalutamide treatment before randomization.
  5. Previous androgen-pathway receptor inhibitors, including enzalutamide, darolutamide, abiraterone or other ARPI. Previous treatment with first generation antiandrogens (i.e. bicalutamide) is allowed.
  6. Chemotherapy or immunotherapy for prostate cancer before randomization.
  7. Treatment with radiotherapy (external-beam radiation therapy, brachytherapy, or radiopharmaceuticals) within 2 weeks before randomization.
  8. Known to any of the study drugs, study drug classes, or in the formulation of the study drugs.
  9. to both computed tomography and magnetic resonance imaging contrast agent.
  10. Prolonged defined as QTcF ≥ 480 ms at screening, based on the mean of triplicate 12-lead ECGs performed after at least 5 minutes of rest. Patients with congenital long QT syndrome will also be excluded.
  11. Any of the following within 6 months before randomization:

    1. stroke,
    2. myocardial infarction,
    3. severe or unstable angina pectoris,
    4. uncontrolled arrhythmia,
    5. coronary or peripheral artery bypass graft, or
    6. congestive heart failure ( class III or IV)
  12. Peripheral neuropathy ≥ grade 2.
  13. Uncontrolled hypertension, indicated by resting systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite medical management.
  14. Prior , except for adequately treated basal-cell or squamous-cell carcinoma of the skin or superficial bladder cancer that had not spread behind the connective-tissue layer (i.e., stage pTis, pTa, or pT1) or any cancer for which treatment had been completed ≥5 years before randomization and from which the patient was disease-free.
  15. A gastrointestinal disorder or procedure that was expected to interfere significantly with absorption of study drug.
  16. Active viral hepatitis, known infection with detectable viral load, or chronic liver disease requiring treatment.
  17. Previous (within 28 days before the start of study drug or 5 half-lives of the treatment of the previous study, whichever was longer) or concomitant participation in another clinical study with investigational medicinal products.
  18. Any other serious or unstable illness or medical, social, or psychological condition that could jeopardize the safety of the patient and/or their compliance with study procedures or might interfere with their participation in the study or evaluation of the study results.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Arm A (experimental arm)

    Docetaxel (75 mg/m2 every three weeks), for 6 planned cycles, plus apalutamide (240 mg, oral single daily dose) and ADT.

    Drug: Apalutamide (Erleada™) 60 mg or 240 mg tablets · Drug: Docetaxel

  • No intervention
    Arm B (control arm)

    Continuation of SOC treatment with apalutamide (240 mg, oral single daily dose) and ADT.

Interventions

  • DrugApalutamideStudies of ApalutamideApalutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The dose of 240 mg (four 60 mg tablets or one single 240 mg tablet) daily of apalutamide is the recommended dose in the SmPC. ADT will be chosen and administered according to standard clinical practice at each participating site and has not been included in the table below.

  • The recommended dose of docetaxel is 75 mg/m2 day 1 every 21 days. Six cycles of docetaxel will be administered.

06

What researchers measure

Primary outcomes

  1. Event-free Survival (EFS)

    Event-free survival is defined as the time from randomization to occurrence of the following events, whichever occurs first in each treatment arm: PSA progression or radiographic progression of soft-tissue, visceral, or bone lesions or death from any cause.

    Time frame: 48 months

Secondary outcomes

  1. Time to castration resistance

    Time to castration resistance is defined as time from randomization to radiographic disease progression, PSA progression per PCWG3 criteria, or symptomatic skeletal event (defined as radiation to bone, pathologic fracture, spinal cord compression, or surgery to bone due to symptoms), whichever occurred first in each treatment arm.

    Time frame: 48 months

  2. Radiographic progression-free survival (rPFS)

    Radiographic Progression-Free Survival is defined as the time from randomization to the first documented evidence of radiographic disease progression, as assessed by the investigator per Prostate Cancer Working Group 3 (PCWG3) criteria for bone lesions and RECIST v1.1 for soft tissue lesions, or death from any cause, whichever occurs first in each treatment arm.

    Time frame: 48 months

  3. PSA progression-free survival

    PSA progression-free survival (PSA-PFS) is defined according to PCWG3 criteria as the time from randomization to the date of PSA progression (a ≥25% increase and an absolute increase of ≥2 ng/mL from nadir, confirmed by a second value ≥3 weeks later) or death from any cause, whichever occurs first in each treatment arm.

    Time frame: 48 months

  4. Overall survival

    Overall survival is defined as time from randomization to date of death from any cause in each treatment arm.

    Time frame: 48 months

  5. Time to subsequent treatment

    Time to subsequent treatment is defined as the time from randomization to the initiation of the first subsequent systemic anticancer therapy after study drugs discontinuation, or death, whichever occurs first in each treatment arm.

    Time frame: 48 months

  6. Deep PSA response rate at 6 months in each treatment arm.

    Deep PSA response is defined as achieving a prostate-specific antigen (PSA) level ≤0.2 ng/mL or PSA Response ≥90% in combination with a PSA ≤ 4 ng/ml.

    Time frame: 6 months

  7. Ultradeep PSA response rate at 6 months in each treatment arm.

    Ultradeep PSA response 1 is defined as achieving a prostate-specific antigen (PSA) level between 0.2 and 0.02 ng/mL. Ultradeep PSA response 2 is defined as achieving a prostate-specific antigen (PSA) level ≤ 0.02 ng/mL.

    Time frame: 6 months

  8. Symptomatic skeletal event-free survival

    Symptomatic skeletal event-free survival (SSE-FS) is defined as the time from randomization to the first occurrence of a symptomatic skeletal event (defined as radiation to bone, pathologic fracture, spinal cord compression, or surgery to bone due to symptoms) or death from any cause, whichever occurred first in each treatment arm.

    Time frame: 48 months

  9. To evaluate the safety profile of treatment intensification with docetaxel plus apalutamide and ADT (Adverse events)

    Percentage of patients with at least one adverse event. Toxicity profile will be assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0. Patients with each adverse event will be calculated over the total number of patients exposed in each treatment arm.

    Time frame: 25 months

  10. Time to initiate opioid use (≥ 7 days)

    Time to initiate opioid use (≥ 7 days) is defined as the time from randomization to the first initiation of opioid analgesic use lasting for 7 or more consecutive days, regardless of the reason, or until death, whichever occurs first in each treatment arm.

    Time frame: 48 months

  11. To evaluate the safety profile of treatment intensification with docetaxel plus apalutamide and ADT (Serious adverse events).

    Patients with at least a serious adverse event will be calculated over the total number of patients exposed in each treatment arm.

    Time frame: 25 months

  12. To evaluate the safety profile of treatment intensification with docetaxel plus apalutamide and ADT (Adverse events leading to treatment discontinuation ).

    Patients with at least an adverse event leading to treatment discontinuation and adverse events leading to death will be calculated over the total number of patients exposed in each treatment arm.

    Time frame: 25 months

  13. To evaluate the safety profile of treatment intensification with docetaxel plus apalutamide and ADT (Death)

    Dead patients calculated over the total number of patients exposed in each treatment arm.

    Time frame: 25 months

  14. To assess the quality of life of patients with FACT-P subscale

    Change from baseline over time in FACT-P subscale in each treatment arm.

    Time frame: 24 months

  15. To assess the quality of life of patients with BPI-SF interference subscale

    Change from baseline over time in BPI-SF interference subscale in each treatment arm.

    Time frame: 24 months

  16. To assess the quality of life of patients with BPI-SF interference subscale.

    Change from baseline over time in BFI subscale in each treatment arm.

    Time frame: 24 months

07

Study locations

1 of 56 sites recruiting
  • CH Bayonne
    Bayonne, France
    Not yet recruiting
    • Louis Francois, MD · Contact
    • Louis Francois, MD · Principal investigator
  • Institut Bergonié
    Bordeaux, France
    Not yet recruiting
    • Guilhem Roubaud, MD · Contact
    • Guilhem Roubaud, MD · Principal investigator
  • CHP Brest - Pasteur
    Brest, France
    Not yet recruiting
    • Ali Hasbini, MD · Contact
    • Ali Hasbini, MD · Principal investigator
  • Hôpital Henri-Mondor
    Créteil, France
    Not yet recruiting
    • Alexandre Ingels, MD · Contact
    • Alexandre Ingels, MD · Principal investigator
  • GHM Cancérologie - Institut Daniel Hollard
    Grenoble, France
    Not yet recruiting
    • Valentine Ruste, MD · Contact
    • Valentine Ruste, MD · Principal investigator
  • Hôpital Franco-Britannique
    Levallois-Perret, France
    Not yet recruiting
    • Caroline Pettenati, MD · Contact
    • Caroline Pettenati, MD · Principal investigator
  • GHBS - Hôpital du Scorff
    Lorient, France
    Not yet recruiting
    • Marie L'Huissier, MD · Contact
    • Marie L'Huissier, MD · Principal investigator
  • Centre De Cancérologie Du Grand Montpellier
    Montpellier, France
    Not yet recruiting
    • Emmanuel Nicolas, MD · Contact
    • Emmanuel Nicolas, MD · Principal investigator
  • Institut du Cancer de Montpellier - Val d'Aurelle (ICM)
    Montpellier, France
    Not yet recruiting
    • Diego Tosi, MD · Contact
    • Diego Tosi, MD · Principal investigator
  • CHU Nîmes
    Nîmes, France
    Not yet recruiting
    • Nadine Houede, MD · Contact
    • Nadine Houede, MD · Principal investigator
  • Hospices Civils de Lyon - HCL
    Paris, France
    Not yet recruiting
    • Denis Maillet, MD · Contact
    • Denis Maillet, MD · Principal investigator
  • Hôpital Européen Georges Pompidou
    Paris, France
    Not yet recruiting
    • Charles Dariane, MD · Contact
    • Charles Dariane, MD · Principal investigator
  • Hôpital Paris Saint-Joseph
    Paris, France
    Not yet recruiting
    • Carole Helissey, MD · Contact
    • Carole Helissey, MD · Principal investigator
  • Hôpital Pitié-Salpêtrière
    Paris, France
    Not yet recruiting
    • Paul Gougis, MD · Contact
    • Paul Gougis, MD · Principal investigator
  • CHU Poitiers
    Poitiers, France
    Not yet recruiting
    • Sheik Emambux, MD · Contact
    • Sheik Emambux, MD · Principal investigator
  • Institut Godinot
    Reims, France
    Not yet recruiting
    • Jean-Christophe Eymard, MD · Contact
    • Jean-Christophe Eymard, MD · Principal investigator
  • CHU de Rennes
    Rennes, France
    Not yet recruiting
    • Romain Mathieu, MD · Contact
    • Romain Mathieu, MD · Principal investigator
  • Polyclinique Saint Georges
    Saint-Georges-de-Didonne, France
    Not yet recruiting
    • Nice Ophélie Cassuto, MD · Contact
    • Nice Ophélie Cassuto, MD · Principal investigator
  • CHP Saint Gregoire
    Saint-Grégoire, France
    Not yet recruiting
    • Aurelien Gobert, MD · Contact
    • Aurelien Gobert, MD · Principal investigator
  • Hôpital Foch
    Suresnes, France
    Not yet recruiting
    • Yann Vano, MD · Contact
    • Yann Vano, MD · Principal investigator
  • Facharztzentrum für Urologie, Uro-Onkologie
    Berlin, Germany
    Not yet recruiting
    • Andreas Haßler, MD · Contact
    • Andreas Haßler, MD · Principal investigator
  • Praxis Berlin / FASANUS - Urologie - Andrologie - Uro-Onkologie
    Berlin, Germany
    Not yet recruiting
    • Andreas Maxeiner, MD · Contact
    • Andreas Maxeiner, MD · Principal investigator
  • Johanniter-Krankenhaus Bonn-Gronau
    Bonn, Germany
    Not yet recruiting
    • Carsten Ohlmann, MD · Contact
    • Carsten Ohlmann, MD · Principal investigator
  • SRH Wald-Klinikum Gera
    Gera, Germany
    Not yet recruiting
    • Susan Foller, MD · Contact
    • Susan Foller, MD · Principal investigator
  • University Hospital Göttingen
    Göttingen, Germany
    Not yet recruiting
    • Arne Strauß, MD · Contact
    • Arne Strauß, MD · Principal investigator
  • Urologische Facharztpraxis Saale
    Halle, Germany
    Not yet recruiting
    • Sandra Seseke, MD · Contact
    • Sandra Seseke, MD · Principal investigator
  • Urologicum Karlsruhe MVZ
    Karlsruhe, Germany
    Not yet recruiting
    • Christoph Vierneisel, MD · Contact
    • Christoph Vierneisel, MD · Principal investigator
  • Klinikum Recklinghausen
    Recklinghausen, Germany
    Not yet recruiting
    • Marco Brock, MD · Contact
    • Marco Brock, MD · Principal investigator
  • University Hospital Rostock
    Rostock, Germany
    Not yet recruiting
    • Angelika Borkowetz, MD · Contact
    • Angelika Borkowetz, MD · Principal investigator
  • ARNAS Garibaldi - Catania
    Catania, Italy
    Not yet recruiting
    • Roberto Bordonaro, MD · Contact
    • Roberto Bordonaro, MD · Principal investigator
  • Hospital Riuniti di Foggia - Foggia
    Foggia, Italy
    Not yet recruiting
    • Vincenza Conteduca, MD · Contact
    • Vincenza Conteduca, MD · Principal investigator
  • National Instute of Oncology - Milan
    Milan, Italy
    Not yet recruiting
    • Giuseppe Procopio, MD · Contact
    • Giuseppe Procopio, MD · Principal investigator
  • Policlinico Gemelli Hospital - Rome
    Roma, Italy
    Not yet recruiting
    • Roberto lacovelli, MD · Contact
    • Roberto Iacovelli, MD · Principal investigator
  • Policlinico Umberto I - Rome
    Roma, Italy
    Not yet recruiting
    • Daniele Santini, MD · Contact
    • Daniele Santini, MD · Principal investigator
  • ULS Alto Ave
    Guimarães, Portugal
    Not yet recruiting
    • Carolina Carvalho, MD · Contact
    • Carolina Carvalho, MD · Principal investigator
  • Hospital Universitario Miguel Servet
    Zaragoza, Aragon, Spain
    Not yet recruiting
    • Carmen Santander, MD · Contact
    • Carmen Santander, MD · Principal investigator
  • Hospital Universitari Vall d´Hebron
    Barcelona, Bacelona, Spain
    Not yet recruiting
    • Dolores Fenor de la Maza, MD · Contact
    • Dolores Fenor de la Maza, MD · Principal investigator
  • Hospital Clínic de Barcelona
    Barcelona, Barcelona, Spain
    Not yet recruiting
    • Marta García de Herreros, MD · Contact
    • Marta García de Herreros, MD · Principal investigator
  • Hospital del Mar
    Barcelona, Barcelona, Spain
    Not yet recruiting
    • Alejo Rodríguez-Vida, MD · Contact
    • Alejo Rodríguez-Vida, MD · Principal investigator
  • Hospital Santa Creu i Sant Pau
    Barcelona, Barcelona, Spain
    Not yet recruiting
    • Mikel Portu, MD · Contact
    • Mikel Portu, MD · Principal investigator
  • ICO Badalona
    Barcelona, Barcelona, Spain
    Not yet recruiting
    • Albert Font, MD · Contact
    • Albert Font, MD · Principal investigator
  • Institut Català d'Oncologia (ICO) L´Hospitalet de Llobregat
    L'Hospitalet de Llobregat, Barcelona, Spain
    Not yet recruiting
    • Jose María Piulats, MD · Contact
    • Jose María Piulats, MD · Principal investigator
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria, Spain
    Not yet recruiting
    • Juan Diego Cacho, MD · Contact
    • Juan Diego Cacho, MD · Principal investigator
  • Hospital Universitario Virgen de las Nieves
    Granada, Granada, Spain
    Not yet recruiting
    • Raquel Luque, MD · Contact
    • Raquel Luque, MD · Principal investigator
  • Hospital Clínico Universitario Santiago de Compostela
    Santiago de Compostela, La Coruña, Spain
    Not yet recruiting
    • Urbano Anido, MD · Contact
    • Urbano Anido, MD · Principal investigator
  • Hospital Universitario 12 Octubre
    Madrid, Madrid, Spain
    Recruiting
    • Enrique Gonzalez-Billalabeitia, MD · Contact
    • Enrique Gonzalez-Billalabeitia, MD · Principal investigator
  • Hospital Universitario Clínico San Carlos
    Madrid, Madrid, Spain
    Not yet recruiting
    • Natalia Vidal, MD · Contact
    • Natalia Vidal, MD · Principal investigator
  • Hospital Universitario La Paz
    Madrid, Madrid, Spain
    Not yet recruiting
    • Alvaro Pinto, MD · Contact
    • Alvaro Pinto, MD · Principal investigator
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid, Spain
    Not yet recruiting
    • Teresa Alonso, MD · Contact
    • Teresa Alonso, MD · Principal investigator
  • Hospital General Universitario Morales Meseguer
    Murcia, Murcia, Spain
    Not yet recruiting
    • Antonio Rosino, MD · Contact
    • Antonio Rosino, MD · Principal investigator
  • Hospital Universitario Virgen de la Victoria
    Málaga, Málaga, Spain
    Not yet recruiting
    • Bernardo Herrera, MD · Contact
    • Bernardo Herrera, MD · Principal investigator
  • Hospital Universitario Virgen Macarena
    Seville, Sevilla, Spain
    Not yet recruiting
    • Alberto Torres, MD · Contact
    • Alberto Torres, MD · Principal investigator
  • Fundación Instituto Valenciano de Oncología
    Valencia, Valencia, Spain
    Not yet recruiting
    • David Llorente, MD · Contact
    • David Llorente, MD · Principal investigator
  • Hospital Clinico Universitario de Valencia
    Valencia, Valencia, Spain
    Not yet recruiting
    • Isabel Chirivella, MD · Contact
    • Isabel Chirivella, MD · Principal investigator
  • Hospital General Universitario de Valencia
    Valencia, Valencia, Spain
    Not yet recruiting
    • Cristina Caballero, MD · Contact
    • Cristina Caballero, MD · Principal investigator
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Valladolid, Spain
    Not yet recruiting
    • Ricardo Sánchez- Escribano, MD · Contact
    • Ricardo Sánchez- Escribano, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2030, 45 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 45 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 12, 2026
StartActual
Jun 5, 2026
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2030
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07333066
Lead sponsor
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Collaborators
Apices Soluciones S.L.
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Jun 5, 2026
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Jun 17, 2026

Study contacts

GUARD
Contact
info@guardconsortium.org
+34 93 452 79 18

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion